Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review - PubMed (original) (raw)
Review
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet et al. Clin Microbiol Infect. 2022 Feb.
Abstract
Background: Vaccines are critical cost-effective tools to control the coronavirus disease 2019 (COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may threaten the global impact of mass vaccination campaigns.
Aims: The objective of this study was to provide an up-to-date comparative analysis of the characteristics, adverse events, efficacy, effectiveness and impact of the variants of concern for 19 COVID-19 vaccines.
Sources: References for this review were identified through searches of PubMed, Google Scholar, BioRxiv, MedRxiv, regulatory drug agencies and pharmaceutical companies' websites up to 22nd September 2021.
Content: Overall, all COVID-19 vaccines had a high efficacy against the original strain and the variants of concern, and were well tolerated. BNT162b2, mRNA-1273 and Sputnik V after two doses had the highest efficacy (>90%) in preventing symptomatic cases in phase III trials. mRNA vaccines, AZD1222, and CoronaVac were effective in preventing symptomatic COVID-19 and severe infections against Alpha, Beta, Gamma or Delta variants. Regarding observational real-life data, full immunization with mRNA vaccines and AZD1222 seems to effectively prevent SARS-CoV-2 infection against the original strain and Alpha and Beta variants but with reduced effectiveness against the Delta strain. A decline in infection protection was observed at 6 months for BNT162b2 and AZD1222. Serious adverse event rates were rare for mRNA vaccines-anaphylaxis 2.5-4.7 cases per million doses, myocarditis 3.5 cases per million doses-and were similarly rare for all other vaccines. Prices for the different vaccines varied from 2.15to2.15 to 2.15to29.75 per dose.
Implications: All vaccines appear to be safe and effective tools to prevent severe COVID-19, hospitalization, and death against all variants of concern, but the quality of evidence greatly varies depending on the vaccines considered. Questions remain regarding a booster dose and waning immunity, the duration of immunity, and heterologous vaccination. The benefits of COVID-19 vaccination outweigh the risks, despite rare serious adverse effects.
Keywords: COVID-19; Coronavirus; Delta; Efficacy; Review; SARS-CoV-2; Seroneutralization; Vaccines; Variants.
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Figures
Fig. 1
Vaccine efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from clinical trials (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 2
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) asymptomatic or symptomatic infection from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 3
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hospitalization or death from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area.
Fig. 4
Vaccine effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from real-world studies (in % and 95%CI) according to the number of doses. Confidence intervals are delimited by the grey rectangular area. Blue, orange, red, pale blue, green refer to Alpha, Beta, Delta, Gamma and unsequenced strains, respectively.
Fig. 5
Average fold reduction in neutralizing response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant versus wild type/D614G SARS-CoV-2 for each coronavirus disease 2019 (COVID-19) vaccine in 54 seroneutralization assays. The line in the middle of the box is the median. The box edges are the 25th and 75th percentiles. These boxplots included different methods assessing neutralizing antibody titres. Methods are detailed in the Supplementary Material Table S2.
Similar articles
- Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A. Rose R, et al. BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x. BMC Med. 2022. PMID: 35057798 Free PMC article. - Covid-19 vaccines and variants of concern: A review.
Hadj Hassine I. Hadj Hassine I. Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9. Rev Med Virol. 2022. PMID: 34755408 Free PMC article. Review. - Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
Chuenkitmongkol S, Solante R, Burhan E, Chariyalertsak S, Chiu NC, Do-Van D, Husin M, Hwang KP, Kiertiburanakul S, Kulkarni PS, Lee PI, Lobo RC, Nghia CH, Ong-Lim A, Sivasampu S, Suah JL, Tok PSK, Thwaites G; SEA Vaccine Effectiveness Expert Working Group. Chuenkitmongkol S, et al. Expert Rev Vaccines. 2022 Sep;21(9):1255-1268. doi: 10.1080/14760584.2022.2092472. Epub 2022 Jun 30. Expert Rev Vaccines. 2022. PMID: 35748494 Review. - Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
Suntronwong N, Kanokudom S, Auphimai C, Assawakosri S, Thongmee T, Vichaiwattana P, Duangchinda T, Chantima W, Pakchotanon P, Chansaenroj J, Puenpa J, Nilyanimit P, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Mongkolsapaya J, Poovorawan Y. Suntronwong N, et al. J Med Virol. 2022 Dec;94(12):5713-5722. doi: 10.1002/jmv.28044. Epub 2022 Aug 10. J Med Virol. 2022. PMID: 35924475 Free PMC article. - Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A, Undurraga EA, Zubizarreta JR, González C, Pizarro A, Acevedo J, Leo K, Paredes F, Bralic T, Vergara V, Mosso M, Leon F, Parot I, Leighton P, Suárez P, Rios JC, García-Escorza H, Araos R. Jara A, et al. Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23. Lancet Glob Health. 2022. PMID: 35472300 Free PMC article.
Cited by
- ASIA syndrome after BNT162b2 vaccination: Is it a distinct rheumatoid arthritis phenotype?
Pekdiker M, Ketenci S. Pekdiker M, et al. Immunol Res. 2024 Sep 16. doi: 10.1007/s12026-024-09540-2. Online ahead of print. Immunol Res. 2024. PMID: 39285049 - Characteristics of health care workers with SARS-CoV-2 at a COVID-19 hospital in Türkiye: Homologous versus heterologous vaccination.
Alıravcı ID, Ertekin YH, Can G, Alkan S. Alıravcı ID, et al. Pak J Med Sci. 2024 Sep;40(8):1702-1708. doi: 10.12669/pjms.40.8.8455. Pak J Med Sci. 2024. PMID: 39281253 Free PMC article. - Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection.
Meng L, Pan Y, Liu Y, He R, Sun Y, Wang C, Fei L, Zhu A, Wang Z, An Y, Wu Y, Diao B, Chen Y. Meng L, et al. Front Immunol. 2024 Aug 27;15:1440819. doi: 10.3389/fimmu.2024.1440819. eCollection 2024. Front Immunol. 2024. PMID: 39257586 Free PMC article. - CoronaVac-vaccinated kidney transplant recipients with hybrid immunity have strong neutralizing responses against Omicron and Mu variants of SARS-CoV-2.
Arias-Murillo YR, Salinas-N MA, Montero C, Giron F, Mercado M. Arias-Murillo YR, et al. Braz J Microbiol. 2024 Sep 10. doi: 10.1007/s42770-024-01507-7. Online ahead of print. Braz J Microbiol. 2024. PMID: 39254799 - COVID-19: vaccination, therapeutics and a review of the science and public health.
Shah SK, Bhandari K, Shah A, Chaurasiya G. Shah SK, et al. Ann Med Surg (Lond). 2024 Jul 17;86(9):5343-5353. doi: 10.1097/MS9.0000000000002374. eCollection 2024 Sep. Ann Med Surg (Lond). 2024. PMID: 39239001 Free PMC article. Review.
References
- World Health Organization Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand... [Internet]. [cité 30 mai 2021]
- Volz E., Mishra S., Chand M., Barrett J.C., Johnson R., Geidelberg L., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021:1–17. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous